Morerecently, promising results obtained in experimental models of ocular diseases haveevidenced that PPAR-γ could be targeted to control inflammation and treat invalidating diseases suchas diabetic retinopathy and optic neuritis, a demyelinating disease of theoptic nerve frequently associated to multiple sclerosis (MS) (see for review [26]).Nonetheless, in spite of the amount of data on the therapeutic activities ofPPAR agonists in EAE, clinical studies are still lacking and reports on theirclinical use in MS or optic neuritis are still anecdotal [27]. This evidence concerns the gene PPARG and optic neuritis.